An Open-Label Multiple-Dose Study of XOMA 358 in Patients with Congenital Hyperinsulinism

Trial Profile

An Open-Label Multiple-Dose Study of XOMA 358 in Patients with Congenital Hyperinsulinism

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs XOMA 358 (Primary)
  • Indications Hyperinsulinaemia; Hypoglycaemia
  • Focus Therapeutic Use
  • Sponsors XOMA
  • Most Recent Events

    • 19 Oct 2016 According to Xoma Corporation media release, the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted in principle the Company's proposal to initiate this study.
    • 28 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top